	US 11,666,652 B2
	Electrochemical plasma activated aqueous chemo therapeutics
Brooks M. Hybertson, Boulder, CO (US); Jessica M. Joslin, Fort Collins, CO (US); Justin P. Bzdek, Fort Collins, CO (US); and Derek C. Johnson, Fort Collins, CO (US)
Assigned to Symbios Technologies, Inc., Fort Collins, CO (US)
Filed by Symbios Technologies, Inc., Fort Collins, CO (US)
Filed on Mar. 27, 2020, as Appl. No. 16/832,373.
Application 16/832,373 is a division of application No. 15/585,084, filed on May 2, 2017, granted, now 10,610,590.
Claims priority of provisional application 62/330,713, filed on May 2, 2016.
Prior Publication US 2020/0323982 A1, Oct. 15, 2020
Int. Cl. A61K 41/00 (2020.01); A61K 9/08 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 33/14 (2006.01); A61K 9/00 (2006.01); A61K 33/00 (2006.01)

CPC A61K 41/0023 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 33/00 (2013.01); A61K 33/14 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01)]

7 Claims

1. A method for treating pancreatic cancer, comprising:

providing a solution having a chosen quantity of a single sodium chloride solute dissolved in water;

circulating said single sodium chloride solute solution through an atmospheric pressure air plasma discharge generated using a high-density plasma reactor for a selected period of time, forming thereby a plasma activated solution having a pH;

adding a base to said plasma activated solution to adjust the pH to 7.4±0.1, forming thereby a physiological solution;

adding sodium chloride to said physiological solution to adjust the chosen quantity of sodium chloride to 9±0.1 g per liter of solution, forming thereby an isotonic solution; and

and exposing cells afflicted with pancreatic cancer to said isotonic solution.